Bionano Genomics, Inc. (BNGO)
BNGONASDAQ-CMBiotechnology: Laboratory Analytical Instruments
$1.02
0.0000 (0.00%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $13.99m
- P/E
- –
- EPS, last 4 quarters
- $-1.97
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.9700 to $2.23
- Average volume
- –
- Previous close
- $1.02
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $4.00, +292.2% from here
Earnings
Next report
Dec 2025
+96.3%
Mar 2026
+6.2%
Jun 2026
+8.6%
Sep 2026
-20.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $7.95m | $6.69m | $8.17m | $8.28m |
| Gross profit | $3.40m | $3.25m | $4.31m | $3.95m |
| Operating income | -$8.54m | -$7.90m | -$7.22m | -$6.54m |
| Net income | -$7.93m | -$8.30m | -$7.42m | -$6.45m |
Last four quarters: revenue $31.09m, margin -96.9%, free cash flow –
News
8 latest- Bionano Genomics (BNGO) Q3 2026 Earnings Call TranscriptThe Motley Fool · 3 days ago
- Sarepta Therapeutics (SRPT) Q3 Earnings Lag EstimatesZacks · Nov 5, 2026
- Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains RTTNews · Sep 14, 2026
- Bionano: OGM Studies Reveal High-Risk Genomic Alterations Missed By Standard Cytogenetics RTTNews · Sep 14, 2026
- Bionano Announces Proposed Medicare Coverage For Genome-Wide Hematologic Cancer Testing RTTNews · Sep 10, 2026
- Bionano Genomics (BNGO) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 17, 2026
- Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?Zacks · Jun 8, 2026
- Bionano (BNGO) Q1 2026 Earnings TranscriptThe Motley Fool · Jun 2, 2026
The company
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company's mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- bionano.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.